NCT05383898 - Study to Evaluate D-1553 in Subjects With Lung Cancer | Biotech Hunter

Enrollment

225

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

November 17, 2023

Study Completion Date

May 17, 2024

Conditions

NSCLC

Interventions

DRUG

D-1553

D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

Trial Locations (2)

200030

Shanghai Chest Hospital, Shanghai

310005

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou